Dianthus Therapeutics, Inc. DNTH

NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Flo

Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...

Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...

On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage biotech with no approved product yet, the update reads less like a routine earnings drop and more like a status report on three separate autoimmune disease bets happening […]

NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to ac

NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences. Wells Fargo 21st Annual Healthcare Conference: Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on Sep

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H’28 75% response rate observed in Interim Respond

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs By building on claseprubart’s best-in-class profile, DNTH312 strengt

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with best-in-disease, pipeline-in-a-product p

Recently published Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Dianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in this space. The new data arrive with Dianthus Therapeutics (NasdaqCM:DNTH) shares at $82.07. Dianthus Therapeutics, trading under NasdaqCM:DNTH, is drawing attention after reporting late-stage data for claseprubart in CIDP, with a 75% response rate. The company enters this news with the stock...

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.